Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Dec 18:8:442.
doi: 10.1186/1752-1947-8-442.

Cyclophosphamide-induced posterior reversible encephalopathy syndrome (PRES): a case report

Affiliations
Case Reports

Cyclophosphamide-induced posterior reversible encephalopathy syndrome (PRES): a case report

Jayamalee L Jayaweera et al. J Med Case Rep. .

Abstract

Introduction: Posterior reversible encephalopathy syndrome is a clinicoradiologic entity characterized by headache, seizures, decreased vision, impaired consciousness and white matter oedema in bilateral occipitoparietal regions. Hypertensive encephalopathy, eclampsia, immunosuppressive/cytotoxic drugs, organ transplantation, renal disease, autoimmune diseases and vasculitides are reported risk factors of posterior reversible encephalopathy syndrome. Reports of cyclophosphamide-induced posterior reversible encephalopathy syndrome are rare and occurred in a background of renal failure, fluid overload or active connective tissue disease.

Case presentation: We report a case of posterior reversible encephalopathy syndrome developing as a direct consequence of intravenous cyclophosphamide therapy in a 33-year-old normotensive Sri Lankan woman with lupus nephritis but quiescent disease activity and normal renal function.

Conclusions: This case report highlights the need for awareness and early recognition of this rare but serious adverse effect of cyclophosphamide that occurred in the absence of other known risk factors of posterior reversible encephalopathy syndrome and that early appropriate intervention leads to a good outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Magnetic resonance fluid-attenuated inversion recovery image demonstrating symmetrical, hyper intense, white matter lesions in bilateral posterior occipital regions.
Figure 2
Figure 2
Diffusion-weighted axial magnetic resonance imaging brain image showing no abnormalities.

References

    1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500. doi: 10.1056/NEJM199602223340803. - DOI - PubMed
    1. Min L, Zwerling J, Ocava LC, Chen IH, Putterman C. Reversible posterior leukoencephalopathy in connective tissue diseases. Semin Arthritis Rheum. 2006;35(6):388–395. doi: 10.1016/j.semarthrit.2006.01.003. - DOI - PubMed
    1. Ishimori ML, Pressman BD, Wallace DJ, Weisman MH. Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE? Lupus. 2007;16:436. doi: 10.1177/0961203307078682. - DOI - PubMed
    1. Primavera A, Audenino D, Mavilio N, Cocito L. Reversible posterior leucoencephalopathy syndrome in systemic lupus and vasculitis. Ann Rheum Dis. 2001;60(5):534–537. doi: 10.1136/ard.60.5.534. - DOI - PMC - PubMed
    1. Lee C-H, Lee YM, Ahn SH, Ryu DW, Song JH, Lee M-S. Cyclophosphamide-induced posterior reversible encephalopathy syndrome in a patient with lupus nephritis. J Rheum Dis. 2013;20(2):103–107. doi: 10.4078/jrd.2013.20.2.103. - DOI

Publication types

MeSH terms

LinkOut - more resources